134136-88-2

Upstream product

• 13154-24-0 triisopropylsilyl chloride 
• 70-70-2 4-hydroxypropiophenone 

Downstream Products

• 134136-66-6 4-(triisopropylsilyloxy)-alpha-bromopropiophenone 
• 169332-15-4 1-<4-<(triisopropylsilyl)oxy>phenyl>-2-(4-hydroxy-4-phenylpiperidino)-1-propanone 
• 134136-74-6 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanone 
• 1028309-27-4 2-(4-Hydroxy-4-phenethyl-piperidin-1-yl)-1-(4-triisopropylsilanyloxy-phenyl)-propan-1-one 
• 1027271-92-6 2-[4-Hydroxy-4-(3-phenyl-propyl)-piperidin-1-yl]-1-(4-triisopropylsilanyloxy-phenyl)-propan-1-one 
• 1027520-31-5 2-(4-Hydroxy-4-p-tolyl-piperidin-1-yl)-1-(4-triisopropylsilanyloxy-phenyl)-propan-1-one 

Relevant academic research and scientific papers

Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H3 receptor inverse agonists

A series of novel dihydrobenzoxathiin derivatives was synthesized and evaluated as potent human histamine H3 receptor inverse agonists. After systematic modification of lead 1a, the potent and selective histamine H3 inverse agonist 1-(3-{4-[(2S,3S)-8-methoxy-3-methyl-4,4-dioxido-2,3-dihydro-1,4-benzoxathiin-2-yl]phenoxy}propyl)pyrrolidine (5k) was identified. Compound 5k showed good pharmacokinetic profiles and brain penetrability in laboratory animals. After 3 mg/kg oral administration of 5k, significant elevation of brain histamine levels was observed in rats where the brain H3 receptor was fully occupied.

(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A potent new neuroprotectant which blocks N-methyl-D-aspartate responses

(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (20, CP-101,606) has been identified as a potent and selective N-methyl-D- aspartate (NMDA) antagonist through a structure activity relation (SAR) program based on ifenprodil, a known antihypertensive agent with NMDA antagonist activity. Sites on the threo-ifenprodil skeleton explored in this report include the pendent methyl group (H, methyl, and ethyl nearly equipotent; propyl much weaker), the spacer group connecting the C-4 phenyl group to the piperidine ring (an alternating potency pattern with 0 and 2 carbon atoms yielding the greatest potency), and simple phenyl substitution (little effect). While potent NMDA antagonists were obtained with a two atom spacer, this arrangement also increased α1 adrenergic affinity. Introduction of a hydroxyl group into the C-4 position on the piperidine ring resulted in substantial reduction in α1 adrenergic affinity. The combination of these observations was instrumental in the discovery of 20. This compound potently protects cultured hippocampal neurons from glutamate toxicity (IC50 = 10 nM) while possessing little of the undesired α1 adrenergic affinity (IC50 ~ 20 μM) of ifenprodil. Furthermore, 20 appears to lack the psychomotor stimulant effects of nonselective competitive and channel-blocking NMDA antagonists. Thus, 20 shows great promise as a neuroprotective agent and may lack the side effects of compounds currently in clinical trials.